Chesley Taft & Associates’s VistaGen Therapeutics VTGN Stock Holding History

Chesley Taft & Associates’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-667	Closed	-$2.49K	–	297
2023 Q1	$2.49K	Hold	667	–	–	﹤0.01%	286
2022 Q4	$2.06K	Hold	667	–	–	﹤0.01%	284
2022 Q3	$3K	Hold	667	–	–	﹤0.01%	279
2022 Q2	$18K	Hold	667	–	–	﹤0.01%	286
2022 Q1	$28K	Hold	667	–	–	﹤0.01%	293
2021 Q4	$39K	Hold	667	–	–	﹤0.01%	298
2021 Q3	$55K	Hold	667	–	–	﹤0.01%	296
2021 Q2	$63K	Hold	667	–	–	﹤0.01%	292
2021 Q1	$46K	Buy	+667	New	+$44.5K	﹤0.01%	286

Other funds holding VTGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chesley Taft & Associates's VTGN Position: Q2 2023 in Review

Chesley Taft & Associates sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 667 shares — an estimated $2.49K sold.

Chesley Taft & Associates first reported a position in VTGN in Q1 2021 and held it in 9 quarters. The position peaked at $63K in Q2 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

Chesley Taft & Associates reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
Chesley Taft & Associates sold 667 VistaGen Therapeutics shares in Q2 2023, an estimated $2.49K.
Chesley Taft & Associates first reported a position in VistaGen Therapeutics in Q1 2021 and held it in 9 quarters.
Chesley Taft & Associates's VistaGen Therapeutics position peaked at $63K in Q2 2021.
33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Chesley Taft & Associates's 13F filing for Q2 2023, filed 18 Jul 2023.